Myovant Sciences Announces European Commission Approval for ORGOVYX® (Relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
Summary : ORGOVYX® is the first and only oral and rogend privation therapy for advanced hormone-sensitive prostate cancerin Europe Myovant expects to secure European…